SEC Comment Letter for GALECTIN THERAPEUTICS INC (GALT) (CIK 0001133416) (GALT) — Aug 22, 2019
GALECTIN THERAPEUTICS INC (GALT) (CIK 0001133416)
Date: Aug. 22, 2019 · CIK: 0001133416 · Accession: 0000000000-19-012760
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-233193
Letter
August 19, 2019 Harold Shlevin, Ph.D. Chief Executive Officer Galectin Therapeutics Inc. 4960 Peachtree Industrial Blvd., Suite 240 Norcross, GA 30071 Re:Galectin Therapeutics Inc. Registration Statement on Form S-3 Filed August 9, 2019 File No. 333-233193 Dear Mr. Shlevin: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Ada D. Sarmento at 202-551-3798 with any questions. Sincerely, Division of Corporation Finance Office of Healthcare & Insurance cc: Robert E. Tritt, Esq.
Show Raw Text
August 19, 2019
Harold Shlevin, Ph.D.
Chief Executive Officer
Galectin Therapeutics Inc.
4960 Peachtree Industrial Blvd., Suite 240
Norcross, GA 30071
Re:Galectin Therapeutics Inc.
Registration Statement on Form S-3
Filed August 9, 2019
File No. 333-233193
Dear Mr. Shlevin:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Ada D. Sarmento at 202-551-3798 with any questions.
Sincerely,
Division of Corporation Finance
Office of Healthcare & Insurance
cc: Robert E. Tritt, Esq.